Jyoti Malhotra is a Senior Consulting Editor for ThePrint, an Indian news organization. With a focus on multinational issues, Jyoti writes articles that cover a wide range of topics including politics, international relations, and cultural events. Her work provides insightful analysis and commentary on the complex dynamics between India and its neighboring countries.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jyoti Malhotra’s articles predominantly cover government and politics, with a focus on international relations. She is particularly interested in geopolitical shifts, diplomatic stances, and political developments within South Asia.
Given her coverage attributes and themes covered, Jyoti may be receptive to pitches from experts who can provide analysis or commentary on current geopolitical events in South Asia. Topics such as India's foreign policy, regional elections or tensions between countries could align well with her areas of interest.
As Jyoti focuses heavily on government announcements and legal policy regulations along with event coverage related to international relations and politics, she would likely appreciate insights from credible sources directly involved in these spheres.
This information evolves through artificial intelligence and human feedback. Improve this profile .
THE GREAT GAME: Mystified Indians are asking if the US is OK with breaking up India to create Khalistan?.
By: Misako Nagasaka, Edward Kim
Amanda Herrmann, MD, discusses findings from the 5-year update from CheckMate-9LA investigating nivolumab, ipilimumab, and chemotherapy in patients with metastatic NSCLC.
By: Karen M. Yun, Erminia Massarelli, Amanda Herrmann, Sandip Patel, Ramya Muddasani, Terence T. Sio, Edward Kim, Misako Nagasaka, Jyoti Malhotra
Jyoti Malhotra, MD, MPH, reviews data from the phase III POSEIDON study evaluating durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for patients with metastatic NSCLC.
Continuing discussion on the treatment of patients with EGFR-mutated NSCLC, Sandip P. Patel, MD, discusses the role of EGFR TKIs without chemotherapy.
By: Ramya Muddasani, Edward Kim, Amanda Herrmann, Sandip Patel, Terence T. Sio, Karen M. Yun, Erminia Massarelli, Jyoti Malhotra, Misako Nagasaka
Edward Kim, MD, introduces a CancerNetwork® Face-Off program in which University of California San Diego and City of Hope will present clinical trial data and discuss treatment practices in non–small cell lung cancer (NSCLC).
THE GREAT GAME: Even his worst detractors will concede that the ex-CM is still willing to call out a crisis.
THE GREAT GAME: Electoral ecstasy vs sullen resentment is the hallmark of polls both have fought.
By: Xiaoju Hu, Vignesh Venkat, Gregory Riedlinger, Zhiyuan Shen, Jyoti Malhotra, Subhajyoti De, Xiaoju Hu, Vignesh Venkat, Gregory Riedlinger, Zhiyuan Shen, Jyoti Malhotra, Subhajyoti De, Xiaoju Hu, Vignesh Venkat, Gregory Riedlinger, Zhiyuan Shen
Abstract Somatic genomic rearrangements are hallmarks of cancer. Complex genomic rearrangements (CGRs) involving multiple intertwined structural alterations are often present in tumor genomes.
By: Vignesh Venkat, Xiaoju Hu, Antara Biswas, Ankit Saxena, Jyoti Malhotra, Gregory Riedlinger, Subhajyoti De Vignesh Venkat, Xiaoju Hu, Antara Biswas, Ankit Saxena, Jyoti Malhotra, Gregory Riedlinger, Subhajyoti De Vignesh Venkat, Xiaoju Hu
Abstract Carcinogenesis is characterized not only by the uncontrolled growth of malignant cells but also by the disruption of the normal
THE GREAT GAME: Impasse between Delhi and Chandigarh is turning into a chasm, where conversations are drying up
(833) 317-6278 
